Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Current Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Total Current Liabilities for 15 consecutive years, with $1.5 million as the latest value for Q3 2025.

  • Quarterly Total Current Liabilities fell 45.97% to $1.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Sep 2025, down 45.97% year-over-year, with the annual reading at $2.3 million for FY2025, 3.55% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $1.5 million at IGC Pharma, down from $1.7 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $2.8 million in Q3 2024, with the low at $1.3 million in Q4 2021.
  • Average Total Current Liabilities over 5 years is $2.0 million, with a median of $2.1 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities soared 52.39% in 2023, then tumbled 45.97% in 2025.
  • Over 5 years, Total Current Liabilities stood at $1.3 million in 2021, then rose by 6.02% to $1.4 million in 2022, then skyrocketed by 42.77% to $1.9 million in 2023, then soared by 37.24% to $2.7 million in 2024, then tumbled by 43.02% to $1.5 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $1.5 million, $1.7 million, and $2.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.